No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

SyBridge Technologies Completes Acquisition Of Active Industrial Solutions, Inc. And Active Industrial Solutions Tennessee

Editor: What To Know

  • Founded in 1977, AIS has grown from a mold maker to a tooling solutions provider through continuously investing in the latest technologies and a strong commitment to lean manufacturing.
  • This is a major step in our effort to build unmatched ability to take on large global tooling programs in the future.
  • New York-based private equity firm Crestview Partners established SyBridge in 2019 and committed $200 million of equity to create a market leader spanning across end-markets, geographies, and advanced technological capabilities to provide value-added solutions to its customers.

February 19, 2021

SyBridge Technologies notes this transaction marks the further expansion by SyBridge in the mobility tooling industry, especially in the fast-growing lighting, fascia, and grille segment.

New York-based private equity firm Crestview Partners established SyBridge in 2019 and committed $200 million of equity to create a market leader spanning across end-markets, geographies, and advanced technological capabilities to provide value-added solutions to its customers.

The combination of AIS and Concours will create the largest tooling and mold solutions provider in North America. In additional to greater economy of scale, this acquisition will also expand Concours’ capabilities in highly complex precision tooling solutions for lighting applications.

Headquartered in Windsor, Ontario, AIS is a leader in engineering, manufacturing and servicing complex plastic injection molds and lighting reflex components for the mobility industry. Founded in 1977, AIS has grown from a mold maker to a tooling solutions provider through continuously investing in the latest technologies and a strong commitment to lean manufacturing.

“AIS has been a strong player with an excellent reputation in quality and operations. Taking the best from both companies, we will create a transformative company to better meet customer needs in today’s global tooling industry,” said Andy Aiton, President of Concours. “The combined company will have a strong footprint across Canada, U.S., Mexico and Asia. This is a major step in our effort to build unmatched ability to take on large global tooling programs in the future.”

Tony Nardone, CEO of SyBridge, added, “This transaction also includes a dedicated service facility in Southern U.S., which gives us a total of four customer service centers in North America. As we look to the future, service and technology are key drivers of our growth strategy.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy